DCGI gives nod for Biological E’s COVID-19 vaccine’s phase-II/III trials on kids aged between five and 18 Read more
Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more